Jasper Therapeutics, Inc. scheduled a special stockholder meeting for September 30, 2026. Shareholders will vote on a proposed reverse stock split at a ratio between 1-for-15 and 1-for-35.
The company also seeks to increase authorized common shares from 490 million to 675 million. This expansion facilitates the conversion of preferred shares issued during the Kira Pharmaceuticals acquisition.
Jasper Therapeutics intends to regain compliance with Nasdaq’s $1.00 minimum bid price requirement. The company received an official non-compliance notice on June 3, 2026.